IP Library › Granted Patent US 7,750,018
Granted Patent B2
US 7,750,018 · App. 11/634,422 · Granted Jul 6, 2010

Use of carboxiamidotriazole (CAI) orotate in macular degeneration

Assignee: Tactical Therapeutics, Inc
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,750,018
App. No.
11/634,422
Granted
Jul 6, 2010
Kind
B2
Abstract

Method and composition of Carboxyamidotriazole orotate for treating age-related macular degeneration and other angiogenesis-dependent diseases.

Claims (1)

1. A method of treating neovascular macular degeneration in an individual in need thereof, comprising administering orally or topically, to said individual, an amount of 5 amino 1,2,3-carboxyamidotriazole orotate effective to inhibit said neovascular macular degeneration.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2007
From: SAVVIPHARM INC.
To: TACTICAL THERAPEUTICS INC.
Reel/Frame 019824/0406 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2007
From: KARMALI, RASHIDA A.
To: SAVVIPHARM INC
Reel/Frame 019688/0746 →
Continuity (1)
Related Publication 20080139592A1 · Jun 12, 2008